UNC team discovers interactions vital for hepatitis A virus replication
Pharmaceutical Technology
JULY 5, 2022
The team also found that the oral compound, RG7834, developed by Hoffmann-La Roche, hindered replication at a crucial step, preventing the virus from infecting liver cells. In addition, the research indicates that the compound was safe at the dosage level used in this research and the acute timeframe of the study.
Let's personalize your content